Marijuana Dependence Clinical Trial
Official title:
Buspirone Treatment for Marijuana Dependence
Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
Status | Active, not recruiting |
Enrollment | 175 |
Est. completion date | May 2016 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Must meet DSM-IV criteria for marijuana dependence. - Must be between the ages of 18 and 65 years. - If female and of childbearing potential, must agree to use acceptable methods of birth control for the duration of the trial. - Must consent to random assignment, and be willing to commit to psychosocial behavioral and medication treatment. - Must be able to read and provide informed consent. Exclusion Criteria: - Women who are pregnant, nursing, or plan to become pregnant during the course of the study. - Must not have a history of or current psychotic disorder, bipolar disorder, or eating disorder. - Must not pose a current suicidal or homicidal risk. - Must not meet current criteria for major depression. - Must not have evidence or history of serious hematologic, endocrine, cardiovascular, pulmonary, renal, gastrointestinal or neurologic disease. - Must not require concomitant therapy with psychotropic medication. - Must not be currently dependent on other substances, with the exception of nicotine or caffeine. - Hypersensitivity to buspirone or any other product component. - Patients who, in the investigator's opinion, would be unable to comply with study procedures or assessments, or would be unacceptable study candidates (e.g., poses threat to staff). |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Marijuana-negative Urine Drug Screens (UDS) | Participants submitted a urine sample weekly. Percentage of marijuana negative urine samples were calculated per group. | Participants provided a once-weekly urine sample for twelve weeks | No |
Secondary | Retention in the Study | Number of days subjects remained active in the study | participants were followed for twelve weeks | No |
Secondary | Marijuana Craving | The Marijuana Craving Questionnaire (MCQ) is intended to measure marijuana craving in adults. It measures symptoms on four subscales: expectancy, purposefulness, emotionality, and compulsivity. The scale rates individual items from 1 (least craving) - 7 (most craving) with a composite scoring range of 12-84 and possible subscale scoring range of 3-21. It was administered weekly- reported here is the mean composite score across the 8 week treatment course. | 8 Weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00893269 -
The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep
|
Phase 1 | |
Completed |
NCT00490269 -
Ph1 Marinol Interaction Study - Part 2 - 1
|
Phase 1 | |
Completed |
NCT02579421 -
Hormones and Reduction in Co-users of Marijuana and Nicotine
|
N/A | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT00373295 -
Effect of Baclofen on Marijuana Withdrawal and Relapse
|
Phase 2 | |
Active, not recruiting |
NCT01827332 -
Effect of Oxytocin on Craving and Therapy Response
|
N/A | |
Completed |
NCT01335789 -
Effect of Oxytocin on Stress in Marijuana Users
|
N/A | |
Terminated |
NCT00438139 -
Ph1 Marinol Interaction Study - Part 1 - 1
|
Phase 1 | |
Completed |
NCT02955329 -
Vaping THC From Electronic Cigarettes
|
Phase 3 | |
Completed |
NCT02439814 -
Pregnenolone and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT01039415 -
Attempts to Stop/Reduce Marijuana Among Dependent Users
|
N/A | |
Completed |
NCT01347762 -
Nabilone for Cannabis Dependence: A Pilot Study
|
Phase 2/Phase 3 | |
Completed |
NCT00270803 -
The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana
|
N/A | |
Completed |
NCT01020019 -
Combined Pharmacotherapy for Cannabis Dependency
|
Phase 2/Phase 3 | |
Completed |
NCT02030665 -
Marijuana Treatment Project 4
|
N/A | |
Completed |
NCT00107588 -
Marijuana Treatment Project - 3
|
N/A | |
Completed |
NCT02011516 -
Baclofen Effects on Marijuana Dependence
|
Phase 2 | |
Recruiting |
NCT00598052 -
Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
|
N/A | |
Completed |
NCT00374127 -
Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper
|
Phase 2 | |
Completed |
NCT00350649 -
Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management
|
Phase 2 |